

Beneficiary Information					
1. Beneficiary Last Name:		2. First Name:			
3. Beneficiary ID #:	4. Beneficiary Date of Bi	4. Beneficiary Date of Birth:		5. Beneficiary Gender:	
Prescriber Information					
6. Prescriber Name:		NPI #:			
Mailing address:	Cit	y:	State:		ZIP:
	tion:				
Name:	Phone #:		Fax #:		
Drug Information					
8. Drug Name:	9. Strength:		10. Quantity Per 30 Days:		
11. Length of Therapy:up to 30 days	60 days90 days	_120 days _	180 days	365 days	Other:
Clinical Information					
For Eucrisa, Elidel, pimecrolimus, Proto	pic, and tacrolimus (questions	; 1-7):			
1. Has the beneficiary tried and failed on at least one prescription topical corticosteroid? Yes No					
2. Does the beneficiary have a documented adverse reaction or contraindication that precludes trial of 1 topical corticosteroid?					
YesNo Please list:					
For Non-preferred medication requests:					
3. Has the beneficiary tried and failed any preferred topical anti-inflammatory medications? YesNo					
4. Please list any failed medications or contraindications:					
Please answer the following depending of the requested topical anti-inflammatory:					
5. Eucrisa: Is the beneficiary 3 months old or older? Yes No					
6. Elidel, Pimecrolimus cream, Protopic 0.03%, and Tacrolimus 0.03%: Is the beneficiary 2 years of age or older? Yes No					
7. Protopic 0.1% and Tacrolimus 0.1%: Is the beneficiary 18 years of age or older? Yes No					
For Opzelura (questions 8-11): 8. Is the Beneficiary ≥ 12 years old? YesNo					
9. Does the beneficiary have a diagnosis of mild to moderate atopic dermatitis? Yes No					
10. Is the beneficiary immunocompromised? Yes No					
11. Has the beneficiary had a trial and failure, contraindication, or intolerance to ≥ 2 of the following classes: prescription topical					
corticosteroids, topical calcineurin inhibitor (ex. pimecrolimus, tacrolimus), topical phosphodiesterase-4 inhibitor (ex.					
crisaborole)? YesNo					
Please list					
Opzelura Renewal (questions 8-13):					
12. Does the beneficiary have disease improvement and/or stabilization? Yes No					
13. Has the beneficiary experienced serious treatment-related adverse events ((e.g., serious infections, lymphoma or other					
malignancies, non-melanoma skin cancer, major adverse cardiovascular events [MACE], thrombosis, thrombocytopenia, anemia,					
neutropenia; or lipid elevations)? Yes No					

Signature of Prescriber: ______ *Prescriber signature mandatory Date: _____

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.
